AUTHOR=Zöhrer Patrick A. , Hana Claudia A. , Seyed Khoei Nazlisadat , Mölzer Christine , Hörmann-Wallner Marlies , Tosevska Anela , Doberer Daniel , Marculescu Rodrig , Bulmer Andrew C. , Herbold Craig W. , Berry David , Wagner Karl-Heinz TITLE=Gilbert’s Syndrome and the Gut Microbiota – Insights From the Case-Control BILIHEALTH Study JOURNAL=Frontiers in Cellular and Infection Microbiology VOLUME=11 YEAR=2021 URL=https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2021.701109 DOI=10.3389/fcimb.2021.701109 ISSN=2235-2988 ABSTRACT=
The heme catabolite bilirubin has anti-inflammatory, anti-oxidative and anti-mutagenic effects and its relation to colorectal cancer (CRC) risk is currently under evaluation. Although the main metabolic steps of bilirubin metabolism, including the formation of stercobilin and urobilin, take place in the human gastrointestinal tract, potential interactions with the human gut microbiota are unexplored. This study investigated, whether gut microbiota composition is altered in Gilbert’s Syndrome (GS), a mild form of chronically elevated serum unconjugated bilirubin (UCB) compared to matched controls. Potential differences in the incidence of CRC-associated bacterial species in GS were also assessed. To this end, a secondary investigation of the BILIHEALTH study was performed, assessing 45 adults with elevated UCB levels (GS) against 45 age- and sex-matched controls (C). Fecal microbiota analysis was performed using 16S rRNA gene sequencing. No association between mildly increased UCB and the composition of the gut microbiota in this healthy cohort was found. The alpha and beta diversity did not differ between C and GS and both groups showed a typical representation of the known dominant phyla. Furthermore, no difference in abundance of